Skip to main content
SpringerLink
Log in

Schizophrenia Treatment Strategies

  • Chapter
Neurotherapeutics

Part of the book series: Contemporary Neuroscience ((CNEURO))

Abstract

To appreciate the need for, and the goals of new strategies for the pharmacotherapy of schizophrenia, it is important to have an understanding of this disorder, including its course and the risks, benefits, and limitations of current treatments. Although this chapter is written with the treatment of schizophrenia as the primary focus, it is important to keep in mind that antipsychotic drugs are also widely used in the treatment of mania, psychotic depression, and a wide variety of organic psychoses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Altman J (1992) Programmed cell death: the paths to suicide. Trends Neurosci 15: 278–280.

    PubMed  CAS  Google Scholar 

  • Arora RC, Meltzer HY (1991) Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neurotransm 85: 19–29.

    CAS  Google Scholar 

  • Arora RC, Meltzer HY (1993) Serotonin2 receptor binding in blood platelets of schizophrenic patients. Psychiatry Res 47: 111–119.

    PubMed  CAS  Google Scholar 

  • Ashby Jr CR, Minabe Y, Edwards I, Wang RY (1991) Comparison of the effects of various typical and atypical antipsychotic drugs on the suppressant action of 2-methylserotonin on medial prefrontal cortical cells in the rat. Synapse 8: 155–161.

    PubMed  CAS  Google Scholar 

  • Ashby Jr CR, Wang RY (1990) Effect of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex: microiontophoretic studies. Brain Res 506: 346–348.

    PubMed  CAS  Google Scholar 

  • Baldessarini R, Frankenberg F (1991) Clozapine: a novel antipsychotic agent. New Engl J Med 324: 746–754.

    PubMed  CAS  Google Scholar 

  • Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992) Do central anti-adrenergic actions contribute to the atypical properties of clozapine? Br J Psych 160: 12–16.

    Google Scholar 

  • Bardgett ME, Wrona CT, Newcomer JW, Csernansky JG (1993) Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmacol 230: 245–250.

    PubMed  CAS  Google Scholar 

  • Basnakian AG, James SJ (1994) A rapid and sensitive assay for the detection of DNA fragmentation during early phase of apoptosis. Nucleic Acids Res 22: 2714, 2715.

    Google Scholar 

  • Benes FM, McSparren J, Bird ED, San Giovanni JP, Vincent SL (1991) Deficits in small intemeurons in prefrontal and cingulate cortices of schizophrenic patients. Arch Gen Psych 48: 996–1001.

    CAS  Google Scholar 

  • Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Cian N (1986) Neurolepticinduced extrapyramidal side effects: clinical perspectives with ritanserin (R35667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40: 492–499.

    Google Scholar 

  • Björk A, Bergman I, Gustaysson G (1992) Amperozide in the treatment of schizophrenic patients: a preliminary report. In: Novel antipsychotic drugs ( Meltzer HY, ed), pp 59–66, New York: Raven.

    Google Scholar 

  • Blandina P, Goldfarb J, Craddock-Royal B, Green JP (1989) Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum. J Pharmacol Exp Ther 251: 803–809.

    PubMed  CAS  Google Scholar 

  • Bleich A, Brown S-L, Kahn R, Van Praag HM (1988) The role of serotonin in schizophrenia. Schizophr Bull 14: 297–316.

    PubMed  CAS  Google Scholar 

  • Bouthenet M-L, Souil E, Martres M-P, Sokoloff P, Giros B, Schwartz J-C (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564: 203–219.

    PubMed  CAS  Google Scholar 

  • Bright JJ, Khan A (1994) Apoptosis: programmed cell death in health and disease. Basic Rep 14: 67–81.

    CAS  Google Scholar 

  • Canton H, Verriéle L, Colpaert FC (1991) Binding of typical and atypical anti-psychotics to 5-HT1c and 5-HT2 sites: clozapine potently interacts with 5-HT sites. Eur J Pharmacology 191: 93–96.

    Google Scholar 

  • Carboni E, Acquas E, Frau R, Di Chiara G (1989a) Differential effects of 5-HT3 antagonists on drug-induced stimulation of dopamine release. Eur J Pharmacol 164: 515–519.

    PubMed  CAS  Google Scholar 

  • Carboni E, Acquas E, Leone P, Di Chiara G (1989b) 5-HT3 receptor antagonists block morphine-and nicotine-but not amphetamine-induced reward. Psychopharmacology 97: 175–178.

    Google Scholar 

  • Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179–186.

    PubMed  CAS  Google Scholar 

  • Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson’s disease. Trends Neurosci 13: 272–277.

    PubMed  CAS  Google Scholar 

  • Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99 (Suppl): S47 - S53.

    PubMed  Google Scholar 

  • Chen J, Van Praag HM, Gardner EL (1991) Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res 543: 354–357.

    PubMed  CAS  Google Scholar 

  • Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25–40.

    PubMed  CAS  Google Scholar 

  • Collard KJ, Edwards R, Lui Y (1992) Changes in synaptosomal glutamate release during postnatal development in the rat hippocampus and cortex. Develop Brain Res 71: 37–43.

    Google Scholar 

  • Cook L, Tam SW, Rohrback KW (1992) [1-(Cyclopropylmethyl)-4-(2’(4“-fluorophenyl)-2’-oxyethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects. J Pharmacol Exp Ther 263: 1159–1166.

    Google Scholar 

  • Corbett R, Hartman H, Kerman L, Woods AT, Strupczewski JT, Helsey GC, Conway PC, Dunn RW (1993) Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 45: 9–17.

    PubMed  CAS  Google Scholar 

  • Costa J, Khaled E, Sramek J, Bunney WE, Potkin SG (1990) An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Psychopharmacol 10: 71, 72.

    Google Scholar 

  • Costall B, Domeney AM, Naylor RJ, Tyers MB (1987) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92: 881–894.

    PubMed  CAS  Google Scholar 

  • Crawley JN (1991) Cholecystokinin-dopamine interactions. Trends Pharmacol Sci 12: 232–236.

    PubMed  Google Scholar 

  • Dall’Olio R, Gandolfi O (1993) The NMDA positive modulator D-cycloserine potentiates the neuroleptic activity of Di and D2 dopamine receptor blockers in the rat. Psychopharmacology 10: 165–168.

    Google Scholar 

  • Daly DA, Moghaddam B (1993) Actions of clozapine and haloperidol in the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152: 61–64.

    PubMed  CAS  Google Scholar 

  • Daly SA, Waddington JL (1993) Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other “D-2-like” agonists. Neuro-pharmacology 32: 509, 510.

    Google Scholar 

  • Deakin JFW, Slater P, Simpson MDC, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ (1989) Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52: 1781–1786.

    PubMed  CAS  Google Scholar 

  • DeVeaugh-Geiss J, McBain S, Gooksey PG, Bell JM (1992) The effects of a novel 5-HT, antagonist, ondansetron, in schizophrenia: results from uncontrolled trials. In: Novel atypical antipsychotics ( Meltzer HY, ed), pp 225–232, New York: Raven.

    Google Scholar 

  • Ellenbroek BA, Artz MT, Cools AR (1991) The involvement of dopamine D, and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur J Pharmacol 196: 103–108.

    PubMed  CAS  Google Scholar 

  • Farber NB, Price MT, Labrugere J, Hemnich J, St. Peter J, Olney JW (1993) Protection against NMDA antagonist neurotoxicity by clozapine and repeated analog correlates with antipsychotic efficacy. Neurosci Abstr 19:384.

    Google Scholar 

  • Farde L, Wiesel FA, Nordström AL, Sedvall G (1989) D1- and D,-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99 (Suppl): S28 — S31.

    PubMed  Google Scholar 

  • Garlow S, Morilak D, Dean RS, Roth BL, Ciaranello RD (1993) Production and characterization of an antibody for the 5-HT, receptor which labels a subpopulation of rat forebrain neurons. Brain Res 615: 113–120.

    PubMed  CAS  Google Scholar 

  • Garver DL, Bissette G, Yao JK, Nemeroff CB (1991) CSF neurotensin concentrations in psychosis: relationship to symptoms and drug response. Am J Psych 148: 485–488.

    Google Scholar 

  • Gellman RL, Aghajanian GK (1993) Pyramidal cells in periform cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. Brain Res 600: 63–73.

    PubMed  CAS  Google Scholar 

  • Gerlach J (1991) New antipsychotics. Classification, efficacy and adverse effects. Schizophr Bull 17: 289–310.

    PubMed  CAS  Google Scholar 

  • Gerner RH, Van Kammen DP, Ninan PT (1985) Cerebrospinal fluid cholecystokinin, bombesin and somatostatin in schizophrenia and normals. Prog Neuro-Psychopharmacol Biol Psych 9: 73–82.

    CAS  Google Scholar 

  • Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison R (1994) BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10: 37–40.

    PubMed  CAS  Google Scholar 

  • Gilbert PL, Harris WJ, McAdams LA, Jeste DA (1995) Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psych 52: 173–178.

    CAS  Google Scholar 

  • Goff DC, Amico E, Dreyfuss E, Ciraulo D (1994) A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. Am J Psych 151: 429–431.

    CAS  Google Scholar 

  • Goff DC, Midha KK, Brotman AW, McCormick S, Waites M, Amico ET (1991) An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11: 193–197.

    PubMed  CAS  Google Scholar 

  • Grace AA (1991) Phasic versus tonic dopamine release in the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1–24.

    PubMed  CAS  Google Scholar 

  • Greenamyre T, Penney JB, Young AB, Hudson C, Silverstein FS, Johnston MV (1987) Evidence for transient perinatal glutamateric innervation ofglobus pallidus. J Neurosci 7: 1022–1030.

    PubMed  CAS  Google Scholar 

  • Gunne LM, Andren PE (1993) An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 16: 90–95.

    PubMed  CAS  Google Scholar 

  • Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psych 34: 702–712.

    CAS  Google Scholar 

  • Hale LD, Herrod JJ, Carpenter TA, McKenna PJ (1994) Magnetic resonance imaging in schizophrenia: a review of clinical and methodological issues. In: Schizophrenia: exploring the spectrum of psychosis ( Ancill RJ, Holliday S, Hogenbottam J, eds), pp 115–136, London: Wiley.

    Google Scholar 

  • Hashimoto T, Nishino N, Nakai H, Tanaka C (1991) Increase in serotonin 5-HTIA receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48: 355–363.

    PubMed  CAS  Google Scholar 

  • Heckers S, Heinsen H, Gerger B, Beckmann H (1991) Hippocampal neuron number in schizophrenia. Arch Gen Psych 48: 1002–1008.

    CAS  Google Scholar 

  • Hoenicke EM, Vanecek SA, Woods JH (1992) The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptaminelc and 5-hydroxytryptamine2 receptors. J Pharmacol Exp Ther 263: 276–284.

    PubMed  CAS  Google Scholar 

  • Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm [Gen Sect] 89: 1–10.

    CAS  Google Scholar 

  • Hutson PH, Bristow LS, Thorn L, Tricklebank MD (1991) R(+)-HA-966, a glycine/ NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br J Pharmacol 103: 2037–2044.

    PubMed  CAS  Google Scholar 

  • Jakob H, Beckmann H (1986) Prenatal developmental disturbances in the limbic allocortex in schizophrenia. J Neural Transm 65: 303–326.

    PubMed  CAS  Google Scholar 

  • Jiang LH, Ashby Jr CR, Kasser RJ, Wang RY (1990) The effect of intraventricular administration of the 5-HT3 receptor agonist 2-methylserotonin on the release of dopamine in the nucleus accumbens: an in vivo chronocoulometric study. Brain Res 513: 156–160.

    PubMed  CAS  Google Scholar 

  • Jones SM, Snell LD, Johnson KM (1987) Inhibition by phencyclidine of excitatory amino acid-stimulating release of neurotransmitter in the nucleus accumbens. Neuropharmacology 26: 173–179.

    PubMed  CAS  Google Scholar 

  • Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1993) Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenia. Neuropsychopharmacology 8: 315–335.

    PubMed  CAS  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796.

    Google Scholar 

  • Kemp JA, Leeson PD (1993) The glycine site of the NMDA receptor—five years on. TIPS 14: 20–25.

    CAS  Google Scholar 

  • Kennedy JE, Petronis A, Macciardi FM, Van Tol HHM, Cola P, Meltzer HY (1993) Genetic studies of clozapine response in schizophrenia. American College of Neuropsychopharmacology Abstracts, San Juan, Puerto Rico.

    Google Scholar 

  • Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20: 379–382.

    PubMed  CAS  Google Scholar 

  • Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDA receptors expressed in Xenopus oocytes. Science 241: 835–837.

    PubMed  CAS  Google Scholar 

  • Lahti RA, Evans DL, Stratman NC, Figur LM (1993) Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 236: 483–486.

    PubMed  CAS  Google Scholar 

  • Largent BL, Wikstrom H, Gundlach AL, Snyder SH (1984) Psychotomimetic opiate receptors labeled and visualized with (+) [3H]3(3-hydroxyphenyl)-N-(lpropyl)piperidine. Proc Natl Acad Sci USA 81: 4983–4987.

    PubMed  CAS  Google Scholar 

  • Largent BL, Wikstrom H, Snowman AM, Snyder SH (1988) Novel antipsychotic drugs share high affinity of sigma receptors. Eur J Pharmacol 155: 345–347.

    PubMed  CAS  Google Scholar 

  • Lawson CF, Mortimore RA, Schlachter SK, Smith MW (1994) Pharmacology of a human dopamine D4 receptor expressed in HEK 293 cells. Methods Findings Exp Clin Pharmacol 16: 303–307.

    CAS  Google Scholar 

  • Lewander T, Westerbergh S-E, Morrison D (1990) Clinical profile of remoxipridea combined analysis of a comparative double-blind, multicentre trial programme. Acta Psychiatrica Scand 82 (Suppl 358): 92–98.

    Google Scholar 

  • Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5-HT2 receptors. Psychopharmacology 112 (Suppl): S40 - S54.

    PubMed  CAS  Google Scholar 

  • Lidsky TI, Alter E, Banerjee SP (1991) Effects of clozapine on glutamatergic transmission. Soc Neurosci Abstr 17: 686.

    Google Scholar 

  • Lidsky TI, Banerjee SP (1992) Clozapine’s mechanism of action: non-dopaminergic activity rather than anatomical selectivity. Neurosci Lett 136: 100–103.

    Google Scholar 

  • Lindström LH, Widerlov E, Bissette G, Nemeroff CB (1988) Reduced CSF neuro- tensin concentration in drug-free schizophrenic patients. Schizophr Res 1: 55–59.

    PubMed  Google Scholar 

  • Lloyd KG, Hornykiewicz O (1977) Effects of chronic neuroleptic or L-DOPA admin- istration on GABA levels in the rat substantia nigra. Life Sci 21: 1489–1495.

    PubMed  CAS  Google Scholar 

  • Malmberg A, Jackson DM, Eriksson A, Mohell N (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol 43: 749–754.

    PubMed  CAS  Google Scholar 

  • Mangano RM, Schwarcz R (1983) Chronic infusion of endogenous excitatory amino acids into rat striatum and hippocampus. Brain Res Bull 10: 47–51.

    PubMed  CAS  Google Scholar 

  • Mason SL, Reynolds GP (1992) Clozapine has sub-micromolecular affinity for 5-HTIA receptors in human brain tissue. Eur J Pharmacol 221: 397, 398.

    Google Scholar 

  • McBean GJ, Roberts PJ (1984) Chronic infusion of L-glutamate causes neurotoxicity in rat striatum. Brain Res 290: 372–375.

    PubMed  CAS  Google Scholar 

  • McPherson SE, Loo P, Brauwalder A, Wood PL (1987) Enhancement of the in vivo binding of [3H]flunitrazepam by the atypical neuroleptic, clozapine. Neuro-pharmacology 26: 265–269.

    CAS  Google Scholar 

  • Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacol 99: S18 - S27.

    Google Scholar 

  • Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17: 263–287.

    PubMed  CAS  Google Scholar 

  • Meltzer HY (1992) The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psych 160 (Suppl 17): 22–29.

    Google Scholar 

  • Meltzer HY (1994a) The concept of atypical antipsychotics. In: Advances in the neurobiology of schizophrenia (den Boer JA, Westenberg HGM, van Praag HM, eds), London, UK: Wiley (in press).

    Google Scholar 

  • Meltzer HY (1994b) Dopamine, serotonin and hormones: relation to psychopathology. In: Schizophrenia—an integrated view (Fog R, ed). Presented at Alfred Benzon Symposium No. 38. Denmark: Munksgaard International Pub (in press).

    Google Scholar 

  • Meltzer HY, Chai BL, Thompson PA, Yamamoto BK (1994a) Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J Pharmacol Exp Ther 268: 1452–1461.

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Fang VS, Young MA (1980) Clozapine-like drugs. Psychopharmacol Bull 16: 32–34.

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251: 238–246.

    PubMed  CAS  Google Scholar 

  • Meltzer HY, Yamamoto BK, Lowy MT, Stockmeier CA (1994b) The mechanism of action of atypical antipsychotic drugs: an update. In: Biology of schizophrenia and affective disease, vol 73 ARNMD Series (Watson SJ, Akil H, eds), New York: Raven (in press).

    Google Scholar 

  • Mercugliano M, Sailer CF, Salama AI, U’Prichard DC, Chesselet M-F (1992) Clozapine and haloperidol have differential effects on glutamic acid decarboxylase mRNA in the pallidal nuclei of the rat. Neuropsychopharmacology 6: 179–187.

    PubMed  CAS  Google Scholar 

  • Meshul CK, Janowsky A, Casey DE, Stallbaumer RK, Taylor B (1992) Coadministration of haloperidol and SCH-23390 prevents the increase in “perforated” synapses due to either drug alone. Neuropsychopharmacology 7: 285–293.

    PubMed  CAS  Google Scholar 

  • Milian MJ, Gobert A, Laurelle G, Brocco M (1993) Potential antidepressive and antipsychotic properties of the high efficacy methoxynapthylpiperazine 5-HT1A agonists, S14506 and S14671. Neurosci Abstr 19: 597.

    Google Scholar 

  • Mita T, Hanada S, Nishono N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C (1986) Decreased serotonin S, and increased dopamine D2 receptors in chronic schizophrenics. Biol Psych 21: 1407–1414.

    CAS  Google Scholar 

  • Mizuki Y, Kajimura N, Kai S, Suetsugi M, Ushijima I, Yamada M (1992) Effects of mianserin in chronic schizophrenia. Prog Neuro-Psychopharmacol Biol Psych 16: 517–528.

    CAS  Google Scholar 

  • Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1775–1760.

    Google Scholar 

  • Morilak DA, Garlow SJ, Ciaranello RD (1993) Immunocytochemical localization and description ofneurons expressing serotoninz receptors in the rat brain. Neurosci 54: 701–717.

    CAS  Google Scholar 

  • Neal-Beliveau BS, Joyce JN, Lucki I (1993) Serotonergic involvement in haloperidolinduced catalepsy. J Pharmacol Exp Ther 265: 207–217.

    PubMed  CAS  Google Scholar 

  • NemeroffCB, Bissette G, Widerlov E, Beckman E, Gerner HH, Manberg R, Lindström PJ, Prang AJ, Gattaz W (1989) Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia and premenstrual syndrome. J Neuropsych Clin Neurosci 1: 16–20.

    Google Scholar 

  • Nemeroff CB, Prang AJ, Gattaz W (1992) Neurotensin, antipsychotic drugs and schizophrenia. Ann New York Acad Sci 146: 146–156.

    Google Scholar 

  • Newcomer JW, Faustman WO, Csernansky JG (1992) Zaclopride in schizophrenia: a single-blind serotonin type 3 antagonist. Arch Gen Psych 49: 751, 752.

    Google Scholar 

  • Oakley NR, Hayes AG, Sheehan MJ (1991) Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigrostriatal dopaminergic pathways in the rat. Psychopharmacology 105: 204–208.

    PubMed  CAS  Google Scholar 

  • Ögren S-O, Florvall L, Hall H, Magnusson O, Angeby-Möller K (1990) Neuropharmacological and behavioral properties of remoxipride in the rat. Acta Psychiatrica Scand 82 (Suppl 358): 21–26.

    Google Scholar 

  • Olney JW (1991) Excitotoxic amino acids and neuropsychiatric disorders. Arch Gen Pharmacol 30: 47–71.

    Google Scholar 

  • Olpe HR (1981) The cortical projection of the dorsal raphe nucleus: some electrophysiological and pharmacological properties. Brain Res 216: 61–71.

    PubMed  CAS  Google Scholar 

  • Pehek EA, Meltzer HY, Yamamoto BK (1993) Local administration of ritanserin on ICS 205,930 enhances dopamine and serotonin efflux in rat prefrontal cortex. Am Neurosci Abstr 19: 302.

    Google Scholar 

  • Pehek EA, Yamamoto BK, Meltzer HY (1991) The effects of clozapine on dopamine, 5-HT, and glutamate release in the rat medial prefrontal cortex. Schizophr Res 4: 323.

    Google Scholar 

  • Potkin SG, Costa J, Roy S, Sramek J, Jin Y, Gulasekaram B (1992) Glycine in the treatment of schizophrenia: theory and practical results. In: Novel antipsychotic drugs ( Meltzer HY, ed), pp 179–188, New York: Raven.

    Google Scholar 

  • Rabacchi S, Bailly T, Delhage-Bouchard N, Mariani J (1992) Involvement of the N-methyl-D-aspartate ( NMDA) receptor in synapse elimination during cerebellar development. Science 256: 1823–1825.

    Google Scholar 

  • Rao TS, Contreras PC, Cler JA, Emmett MR, Mick SJ, Iyengar S, Wood PL (1991) Clozapine attenuates n-methyl-o-aspartate receptor complex-mediated responses in vivo tentative evidence for a functional modulation by a noradrenergic mechanism. Neuropharmacology 30: 557–565.

    PubMed  CAS  Google Scholar 

  • Rasmussen K, Czachura JF, Stockton ME, Howbert IT (1991 a) Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY 262691 decreases midbrain dopamine unit activity. Eur J Pharmacol 209: 135–138.

    Google Scholar 

  • Rasmussen K, Czachura JF, Stockton ME, Howbert JJ (1993) Electrophysiological effects of diphenylpyrazolidoinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J Pharmacol Exp Ther 264: 480–488.

    PubMed  CAS  Google Scholar 

  • Rasmussen K, Stockton ME, Czachura JF (1991b) The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A 10 dopamine neurons. Eur J Pharmacol 205: 113–116.

    PubMed  CAS  Google Scholar 

  • Reynolds GP, Czudek C, Andrews HB (1990) Deficit and hemispheric asymmetry of GABA uptake sites in hippocampus in schizophrenia. Biol Psych 27: 1038–1044.

    CAS  Google Scholar 

  • Rivest JM, Audenot V, Gobert A, Cistarelli L, Chaput C, Brocco M, Lavielle G, Millan NJ (1993) Actions of the potent methoxynapthylpiperazine 5-HT,A receptor agonists S 14506 and S14671 at dopamine D1, Dz and D3 receptors in vitro and in vivo Neurosci Abstr 10:597.

    Google Scholar 

  • Roberts GW, Colter N, Lofthouse R, Johnstone EC, Crow TJ (1987) Is there gliosis in schizophrenia? Investigation of the temporal lobe. Biol Psych 22: 1459–1468.

    CAS  Google Scholar 

  • Rosin DL, Clark WA, Goldstein M, Roth RH, Deutch AY (1992) Effects of 6-hydroxydopamine lesions of the prefrontal cortex on tyrosine hydroxylase activity in mesolimbic and nigrostriatal dopamine systems. Neuroscience 48: 831–839.

    PubMed  CAS  Google Scholar 

  • Rossee RB, Schwartz BL, Leighton BL, Davis RE, Deutsch SI (1990) An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin Neuropharmacol 13: 343–354.

    Google Scholar 

  • Roth BL, Ciaranello RD, Meltzer HY (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT 1c receptors. J Pharmacol Exp Ther 260: 1361–1365.

    PubMed  CAS  Google Scholar 

  • Roth BL, Craigo SC, Choudhary MS, Uler A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine6 (5-HT6) and 5-hydroxytryptamine, (5-HT) receptors. J Pharmacol Exp Ther 268: 1406–1410.

    Google Scholar 

  • Rupniak NMJ, Prestwich SA, Horton RW, Jenner P, Marsden CD (1987) Alterations in cerebral glutamic acid decarboxylase and 3H-flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride or clozapine. J Neural Transm 68: 113–125.

    PubMed  CAS  Google Scholar 

  • Sachar EJ, Mason JW, Kolmer Jr HS, Artiss KL (1963) Psychoendocrine aspects of acute schizophrenia reactions. Psychosomatic Med 25: 510–537.

    CAS  Google Scholar 

  • Sapolsky RM, Uno H, Rebert CS, Finch CE (1990) Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 10: 2897–2902.

    PubMed  CAS  Google Scholar 

  • Saykin AJ, Schtasel DL, Gur RE, Kester BD, Mozley LH, Stafiniak P, Gur RC (1994) Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psych 51: 124–131.

    CAS  Google Scholar 

  • See RE, Toga AW, Ellison G (1990) Autoradiographic analysis of regional alteration in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J Neural Transm 82: 93–109.

    CAS  Google Scholar 

  • Seeman P, Guan H-C, Van Tol HHM (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365: 441–445.

    PubMed  CAS  Google Scholar 

  • Seeman P, Niznik HB, Guan C, Seeman MV, Jellinger K, Van Tol HHM, Niznik HB (1992) Link between Di and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 86:10, 156–10, 160.

    Google Scholar 

  • Sheldon PW, Aghajanian GK (1990) Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat periform cortex: evidence for the involvement of a 5-HT2- activated interneuron. Brain Res 506: 62–69.

    PubMed  CAS  Google Scholar 

  • Sheldon PW, Aghajanian GK (1991) Excitatory responses to serotonin (5-HT) in neurons of the rat piriform cortex: evidence for mediation by 5-HT 1c receptors in pyramidal cells and 5-HT2 receptors in pyramidal cells and 5-HT2 receptors in interneurons. Synapse 9: 209–218.

    Google Scholar 

  • Sherman AD, Hegwood TS, Baruagh S, Waziri R (1991) Deficient NMDAmediated glutamate release from synaptosomes of schizophrenics. Biol Psych 30: 1191–1198.

    CAS  Google Scholar 

  • Simpson MDC, Royston MC, Slater P, Deakin JFW, Skam WJ (1989) Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 107: 211–215.

    PubMed  CAS  Google Scholar 

  • Singh L, Donald E, Foster AC, Kudon PH, Iverson LL, Iverson SD, Kemp JA, Lesson PD, Marshall GR, Oles RJ, Priestley T, Thorn L, Tricklebank MD, Vass CA, Williams BJ (1990) Enantiomers of HA-966 (3-amino-l-hydroxypyrrolidzone) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/ NMDA receptor antagonist, but (—)-HA-966 is a potent y-butyolactone-like sedative. Proc Natl Acad Sci USA 87: 347–351.

    PubMed  CAS  Google Scholar 

  • Sloviter RS, Dean E, Newport S (1993) Electron-microscopic analysis of adrenalectomy-induced hippocampal granule cell degeneration in the rat: apoptosis in the adult central nervous system. J Comprehens Neurol 330: 337–351.

    CAS  Google Scholar 

  • Sokoloff P, Giros B, Martres M-P, Bowtherret M-L, Schwartz J-C (1990) Molecular cloning and characterization of a novel dopamine receptor ( D) as a target for neuroleptics. Nature 347: 146–151.

    Google Scholar 

  • Sokoloff P, Martres M-P, Giros B, Bouthenet M-L, Schwartz J-C (1992) The third dopamine receptor ( D) as a novel target for antipsychotics. Biochem Pharmacol 43: 659–666.

    Google Scholar 

  • Sorensen SM, Humphreys TM, Palfreyman MG (1989) Effect acute and chronic MDL 73,147, a 5-HT3 receptor antagonist, on A9 and A10 dopamine cells. Eur J Pharmacol 163: 115–118.

    PubMed  CAS  Google Scholar 

  • Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ. (1993) Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266: 684–691.

    PubMed  CAS  Google Scholar 

  • Squires RF, Saederup E (1991) A review of evidence for GABAergic predominance/ glutamateric deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of “functional” psychosis. Neurochem Res 16: 1009–1111.

    Google Scholar 

  • Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY (1995) Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem candidate nucleus of subjects with schizophrenia or major depression. Brain Res, in press.

    Google Scholar 

  • Suzuki T, Moroji T, Hori T, Baba A, Kaniai N, Koizumi J (1993) Autoradiographic localization of CCK-8 binding sites in the rat brain: effects of chronic methamphetamine administration on these sites. Biol Psych 34: 781–790.

    CAS  Google Scholar 

  • Tam SW, Steinfels GF, Gilligan PJ, Schmidt WK, Cook L (1992) DUP 734 [1(cyclo-propyl-methyl)-4-(2’(4“-fluorophenyl)-2-oxoethyl)-piperidine HBR), a sigma and 5-hydroxytryptamine2 receptor antagonist: receptor binding, electrophysiological and neuropharmacological profiles. J Pharmacol Exp Ther 263: 1167–1174.

    PubMed  CAS  Google Scholar 

  • Tamminga CA, Cascella N, Fakouhi TD, Hefting RL (1992) Enhancement ofNMDAmediated transmission in schizophrenia: effects of milacemide. In: Novel antipsychotic drugs ( Meltzer HY, ed), pp 171–177, New York: Raven.

    Google Scholar 

  • Tandon R, Greden JF(1989) Cholinergic hyperactivity and negative symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 46: 745–753.

    Google Scholar 

  • Taylor DP, Schlemeer RF (1992) Sigma “antagonists”—potential antipsychotics? In: Novel antipsychotic drugs ( Meltzer HY ed), pp 189–201, New York: Raven.

    Google Scholar 

  • Thompson PA, Meltzer HY (1993) Positive, negative and disorganisation factors from the schedule of affective disorders and schizophrenia and the present state examination. A three-factor solution. Br J Psych 163: 111–119.

    Google Scholar 

  • Ulas J, Cotman CW (1993) Excitatory amino acid receptors in schizophrenia. Schizophr Bull 19: 105–117.

    PubMed  CAS  Google Scholar 

  • Van Kammen DP (1991) The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis. Psychol Med 21: 881–895.

    PubMed  Google Scholar 

  • Van Kammen DP, Gelernter J (1987) Biochemical instability in schizophrenia II: the serotonin and gamma-aminobutyric acid systems. In: Psychopharmacology: the third generation of progress, ( Meltzer HY, ed), pp 753–758, New York: Raven.

    Google Scholar 

  • Van Kammen DP, Peters J, Yao J, Van Kammen WB, Neylen T, Shaw D, Linnoila M (1990) Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psych 47: 161–168.

    Google Scholar 

  • Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614.

    PubMed  Google Scholar 

  • Van Tol HHM, Wu CM, Guan H-C, Ohara K, Bunzow JR, Civelli 0, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1992) Multiple dopamine D4 receptor variants in the human population. Nature 358: 149–152.

    PubMed  Google Scholar 

  • Waddington JL (1993) Schizophrenia: developmental neuroscience and pathobiology. Lancet 341: 531–536.

    PubMed  CAS  Google Scholar 

  • Waters N, Svensson K, Haadasma-Svensson SR, Smith MW, Carlsson A (1993) The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm 94: 11–19.

    CAS  Google Scholar 

  • Watling KJ, Beer MS, Stanton JA, Newberry NR (1990) Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervical ganglion of the rat. Eur J Pharmacol 182: 465–472.

    PubMed  CAS  Google Scholar 

  • Waziri R (1988) Glycine therapy of schizophrenia. Biol Psych 23:210,211. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psych 44: 660–669.

    Google Scholar 

  • Wiesel F-A, Nordström A-L, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114: 31–38.

    PubMed  CAS  Google Scholar 

  • Wik G, Wiesel F-A, Eneroth P, Sedvall G, Aström G (1986) Dexamethasone suppression test in schizophrenic patients before and during neuroleptic treatment. Acta Psychiatrica Scand 74: 161–167.

    CAS  Google Scholar 

  • Wiley JL, Porter JH (1992) Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacol Biochem Behav 43: 961–965.

    PubMed  CAS  Google Scholar 

  • Wolkowitz OM, Pickar D (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psych 148: 714–726.

    CAS  Google Scholar 

  • Wolkowitz OM, Turetsky N, Reus VI, Hargreaves WA (1992) Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacol Bull 28: 291–295.

    PubMed  CAS  Google Scholar 

  • Yamamoto BK, Cooperman MA (1994). Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14: 4159–4166.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Herbert Y. Meltzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Zeneca Pharmaceuticals Group, Wilmington, DE, USA

    Linda M. Pullan  & Jitendra Patel  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media New York

About this chapter

Cite this chapter

Meltzer, H.Y. (1996). Schizophrenia Treatment Strategies. In: Pullan, L.M., Patel, J. (eds) Neurotherapeutics. Contemporary Neuroscience. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-466-5_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-466-5_1

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5978-5

  • Online ISBN: 978-1-59259-466-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation